Antiretroviral drugs in development: A report from HIV DART 2006

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Antiretroviral therapy has resulted in significant declines in HIV-associated morbidity and mortality. However, new drugs continue to be needed to sustain and improve on this success. Fortunately, the HIV drug development pipeline is robust and numerous candidate antiretroviral drugs are in various stages of development. Here, we report on antiretroviral drugs in development, as well as new approaches to therapy that were presented at HIV DART 2006 Frontiers in Drug Development for Antiretroviral Therapies.

Original languageEnglish (US)
Pages (from-to)83-92
Number of pages10
JournalDrugs of the Future
Volume32
Issue number1
StatePublished - Jan 2007

Fingerprint

HIV
Pharmaceutical Preparations
Therapeutics
Morbidity
Mortality

ASJC Scopus subject areas

  • Molecular Medicine
  • Drug Discovery
  • Pharmacology

Cite this

Antiretroviral drugs in development : A report from HIV DART 2006. / Temesgen, Zelalem.

In: Drugs of the Future, Vol. 32, No. 1, 01.2007, p. 83-92.

Research output: Contribution to journalArticle

@article{819001d06f66498aaf7529bf78d307a0,
title = "Antiretroviral drugs in development: A report from HIV DART 2006",
abstract = "Antiretroviral therapy has resulted in significant declines in HIV-associated morbidity and mortality. However, new drugs continue to be needed to sustain and improve on this success. Fortunately, the HIV drug development pipeline is robust and numerous candidate antiretroviral drugs are in various stages of development. Here, we report on antiretroviral drugs in development, as well as new approaches to therapy that were presented at HIV DART 2006 Frontiers in Drug Development for Antiretroviral Therapies.",
author = "Zelalem Temesgen",
year = "2007",
month = "1",
language = "English (US)",
volume = "32",
pages = "83--92",
journal = "Drugs of the Future",
issn = "0377-8282",
publisher = "Prous Science",
number = "1",

}

TY - JOUR

T1 - Antiretroviral drugs in development

T2 - A report from HIV DART 2006

AU - Temesgen, Zelalem

PY - 2007/1

Y1 - 2007/1

N2 - Antiretroviral therapy has resulted in significant declines in HIV-associated morbidity and mortality. However, new drugs continue to be needed to sustain and improve on this success. Fortunately, the HIV drug development pipeline is robust and numerous candidate antiretroviral drugs are in various stages of development. Here, we report on antiretroviral drugs in development, as well as new approaches to therapy that were presented at HIV DART 2006 Frontiers in Drug Development for Antiretroviral Therapies.

AB - Antiretroviral therapy has resulted in significant declines in HIV-associated morbidity and mortality. However, new drugs continue to be needed to sustain and improve on this success. Fortunately, the HIV drug development pipeline is robust and numerous candidate antiretroviral drugs are in various stages of development. Here, we report on antiretroviral drugs in development, as well as new approaches to therapy that were presented at HIV DART 2006 Frontiers in Drug Development for Antiretroviral Therapies.

UR - http://www.scopus.com/inward/record.url?scp=34247612996&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34247612996&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:34247612996

VL - 32

SP - 83

EP - 92

JO - Drugs of the Future

JF - Drugs of the Future

SN - 0377-8282

IS - 1

ER -